US4521402A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Constant release rate solid oral dosage formulations of hydrazine
Assignee: Verex Laboratories Inc
•
Filing: 1984-02-17
•
Granted: 1985-06-04
•
Expires: 2004-02-17
Abstract
Abstract A constant order release rate solid oral dosage formulation of hydralazine or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of hydralazine or a pharmaceutically acceptable salt; from about 0.5 to 6.0 weight percent of an acid-retardant or hydrophobic cellulose derivative; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil: from about 1 to 20 weight percent of an acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 percent of a lubricant.
Inventors
- 👤 James M. Dunn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 12:35
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/275; A61K9/00; A61K9/20; A61K9/2004; A61K9/2009; A61K9/2013; A61K9/2022; A61K9/2027; A61K9/205; A61K9/2054
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
104 words
A constant order release solid oral dosage formulation of hydralazine or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of hydralazine or a phramaceutically acceptable salt thereof; from about 0.5 to 6.0 weight percent of one or more cellulose derivatives selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethylcellulose, phthalate ethyl cellulose, and microcrystalline cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 weight percent of a tabletting lubricant.
Claim 2
Dependent Claim
104 words
A constant order release solid oral dosage formulation of hydralazine or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of hydralazine or a phramaceutically acceptable salt thereof; from about 0.5 to 6.0 weight percent of one or more cellulose derivatives selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethylcellulose, phthalate ethyl cellulose, and microcrystalline cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 weight percent of a tabletting lubricant.
Claim 3
Dependent Claim
19 words
The formulation of claim 1 wherein said cellulose derivative is a combination of cellulose acetate phthalate and microcrystalline cellulose.
Claim 4
Dependent Claim
14 words
The formulation of claim 1 wherein said hydrogenated vegetable oil is hydrogenated cottonseed oil.
Claim 5
Dependent Claim
12 words
The formulation of claim 1 wherein said cellulose derivative is microcrystalline cellulose.
Claim 6
Dependent Claim
28 words
The formulation of claim 1 wherein said cellulose derivative is a combination of cellulose acetate phthalate and microcrystalline cellulose, and said hydrogenated vegetable oil is hydrogenated cottonseed oil.
Claim 7
Dependent Claim
21 words
The formulation of claim 1 wherein said cellulose derivative is microcrystalline cellulose and said hydrogenated vegetable oil is hydrogenated cottonseed oil.
Claim 8
Dependent Claim
89 words
A constant order release solid oral dosage formulation of hydralazine or a pharmaceutically acceptable salt thereof comprising: a therapeutically effective amount of hydralazine or a pharmaceutically acceptable salt thereof; from 0.5 to 6.0 weight percent of a combination of microcrystalline cellulose and cellulose acetate phthalate; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4. to 3.0 weight percent of a tabletting lubricant.
Claim 9
Dependent Claim
89 words
A constant order release solid oral dosage formulation of hydralazine or a pharmaceutically acceptable salt thereof comprising: a therapeutically effective amount of hydralazine or a pharmaceutically acceptable salt thereof; from 0.5 to 6.0 weight percent of a combination of microcrystalline cellulose and cellulose acetate phthalate; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4. to 3.0 weight percent of a tabletting lubricant.
Claim 10
Dependent Claim
84 words
A constant order release solid oral dosage formulation of hydralazine of a pharmaceutically acceptable salt thereof comprising: a therapeutically effective amount of hydralazine or a pharmaceutically acceptable salt thereof; from 0.5 to 6.0 weight percent of ethyl cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene; from about 0.5 to 4.0 weight percent of fumed silicon dioxide; and from about 0.4 to 3.0 weight percent of a pharmaceutically acceptable tabletting lubricant.
Claim 11
Dependent Claim
84 words
A constant order release solid oral dosage formulation of hydralazine of a pharmaceutically acceptable salt thereof comprising: a therapeutically effective amount of hydralazine or a pharmaceutically acceptable salt thereof; from 0.5 to 6.0 weight percent of ethyl cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene; from about 0.5 to 4.0 weight percent of fumed silicon dioxide; and from about 0.4 to 3.0 weight percent of a pharmaceutically acceptable tabletting lubricant.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-06-03 | 1988-12-03 | 1989-06-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-06-03 | 1992-12-03 | 1993-06-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-06-03 | 1996-12-03 | 1997-06-04 | $7700.00 | Window Closed / Lapsed |